Q-omics provides the consensus-scored DNAJC5G profile across patient tissues and cancer cell-line models. DNAJC5G expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, DNAJC5G is differentially expressed in 6, with the highest sampling consensus in BRCA. Additionally, DNAJC5G RNA expression shows 11,148 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BRCA, and GBM as cancer lineages where DNAJC5G shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DNAJC5G — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DNAJC5G survival associations across molecular data types. DNAJC5G RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DNAJC5G RNA expression–survival associations across cancer types. High DNAJC5G expression shows unfavorable associations in BRCA, COAD, ESCA, LUAD and KIRC, but favorable associations in LUSC. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for DNAJC5G RNA expression.
This table summarizes DNAJC5G tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for DNAJC5G. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DNAJC5G shows lower tumor expression in BRCA and THCA and higher tumor expression in KIRP, KICH, CHOL and LIHC. The BRCA box plot shows higher DNAJC5G RNA expression in normal versus tumor tissue (log2 FC = −0.066, t-test p < 0.001).
This table shows molecular features associated with DNAJC5G in patient tissues and cancer cell lines. In patient samples, DNAJC5G shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, DNAJC5G RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BONE.
